In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Aptinyx (APTX – Research Report), with a price target of $1.00. The company’s shares closed last Friday at $0.24.
Selvaraju covers the Healthcare sector, focusing on stocks such as Kezar Life Sciences, Synlogic, and Urogen Pharma. According to TipRanks, Selvaraju has an average return of -29.5% and a 21.85% success rate on recommended stocks.
Currently, the analyst consensus on Aptinyx is a Strong Buy with an average price target of $1.67.
See today’s best-performing stocks on TipRanks >>
APTX market cap is currently $15.96M and has a P/E ratio of -0.22.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aptinyx Inc. is a clinical stage biopharmaceutical company. It engages in the discovery, development, and and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G. Riedel and Joseph R. Moskal in June 2015 and is headquartered in Evanston, IL.
